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2. Case history
A 31-year-old, gravida 4, para 2-0-2-2, Caucasian female presented
complaining of sharp abdominopelvic pain radiating to her back. Fur-
thermore, she noted increasing abdominal distension, early satiety,
and bloating for the past 4–5 months. She had a 25 lb weight loss over
that time without dieting. She denied nausea, vomiting, or diarrhea.
She reported regular menses since the age of 11, until recently, when1. Introduction
Sex-cord stromal tumors arise from the ovarian stroma that sur-
rounds and supports the oocytes. They are relatively rare amongovarian
neoplasms, accounting for only 1.2% of ovarian tumors (Quirk and
Natarajan, 2005). These ovarian cancers are generally expected to be
low-grade, diagnosed at an early stage, and lymph node metastases
are exceedingly rare. Sertoli–Leydig tumors, in particular, account for
less than 0.5% of ovarian neoplasms (Al-Agha et al., 2011). Sertoli–
Leydig tumors are a subgroup of sex-cord stromal tumors, which tend
more toward “male” differentiation, hence the term “androblastoma”.
These tumors are comprised of cells normally found in themale gonads
that produce androgens, often resulting in hirsutism and virilization in
up to two-thirds of female patients (DiSaia and Creasman, 1997).
Sertoli–Leydig tumors are typically ﬁrm and solid, composed of tubules
surrounded by ﬁbrous stroma. Most commonly, patients present during
the second and third decades, with an average size of 16 cm in diameter.
Heterologous elements such as cartilage, bone, or striated muscle are
rare ﬁndings in sex-cord stromal tumors, particularly of Sertoli–Leydig
differentiation. We present the ﬁrst documented case that includes
three rare ﬁndings within the same sex-cord stromal tumor: Sertoli–
Leydig differentiation, heterology, and sarcomatoid overgrowth. HereinOncology, Roswell Park Cancer
. Brightwell).
. This is an open access article underher menses began to consist of mostly spotting. She had regular visits
with her gynecologist, the last approximately 8 months ago, at which
time she had a normal exam. She took an oral contraceptive for birth
control.
Her past medical history was only signiﬁcant for exercise-induced
asthma. Surgical history consisted of a myringotomy as a child and a
suction D&C for termination of pregnancy. She had no known drug
allergies. Her family history was signiﬁcant for a paternal great-
grandmother with ovarian cancer and paternal grandmother with
breast cancer. The patient admitted to occasional marijuana use but de-
nied alcohol and other illicit drug use. Though she no longer smoked
cigarettes at the time of presentation, she reported a four pack–year
history.
On physical exam, she was afebrile with normal vital signs. There
was no cervical, supraclavicular, or inguinal lymphadenopathy. The ab-
domen was tense, with palpable mass effect extending approximately
5 cm above the umbilicus. Pelvic exam revealed grossly normal external
genitalia. On bimanual examination, the mass was again appreciated
ﬁlling the pelvis and extending into the abdomen. Due to the volume
of the mass, the uterus was not well palpated, and the patient did not
tolerate rectovaginal exam. Laboratory values were signiﬁcant for a
CA-125 of 271.2 U/mL and AFP of 87.9 ng/mL. All other relevant labs
were normal. Computed tomography revealed a 25 × 22 × 15 cm
mass, likely arising from the left adnexa, comprised of solid and cystic
components. There was minimal ascites with no evidence of retroperi-
toneal lymphadenopathy or bowel obstruction.
We proceeded to surgery, noting that the patient preferred fertility
preservation. A vertical midline incision extending from the symphysis
pubis tomidway between the umbilicus and xiphoid processwasmade.
Upon entering the abdomen, the mass was noted to arise from the left
ovary, with tumor involving the surface. Clear, straw-colored ascitesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tumor. There were no other metastatic implants visualized in the abdo-
men or pelvis. A small cystic pouch on the external surface of the mass
was incidentally ruptured during the extraction, making her a clinical
stage IC1. The patient's postoperative course was uneventful. The ﬁnal
pathologic report reﬂected Sertoli–Leydig tumor with heterologous
elements and a high-grade component with sarcomatoid features.
Omental tissue showed a benign ﬁnding of leiomyomatosis peritonealis
disseminata-like changes. The measured size of the ovary was
34 × 31 × 19 cm with 75% solid and 25% cystic components. Immuno-
histochemistry showed positive staining for desmin, MYO D1, and
focal myogenin, cytokeratin AE 1/3 and inhibin-α (Fig. 1). Desmin is
typically positive in striated and smoothmuscle,MYOD1 andmyogenin
are striated muscle markers, cytokeratin AE 1/3 is positive in epithelial
cell elements, and inhibin-α is a goodmarker for some sex-cord stromal
tumors and positive in Leydig cells. After discussion of her case at our
multidisciplinary tumor board conference and given the fact that she
had high-grade, sarcomatoid features, it was decided to give the patient
carboplatin and taxol for six cycles, however the patient suffered a taxol
reaction during her second cycle and was switched to carboplatin and
taxotere for the remaining four cycles. She is currently eighteenmonths
postoperativewithout evidence of diseasewith normal AFP andCA-125.
3. Discussion
Approximately 10% of Sertoli–Leydig tumors of the ovary are well-
differentiated with a large majority of the histological component
consisting of Leydig cells in the stroma (Lenhard et al., 2007). Heterolo-
gous tumors, accounting for 20% of Sertoli–Leydig neoplasms, differ in
that they are more predominantly cystic than their homologousFig. 1. 1) Sheets of spindle cells representing the frankly sarcomatous areas of this malignant Se
ylin and eosin stain. Original magniﬁcation: 200×. 2) Area of tumor showing Sertoliform tubu
(cartilage) in this malignant Sertoli–Leydig tumor. Hematoxylin and eosin stain. Original magn
cells show abundant cytoplasm and an occasional Reinke crystal. Hematoxylin and eosin staincounterparts.Mesenchymal heterology is typically seenwith poorly dif-
ferentiated tumors and is associated with worse clinical prognoses.
Most commonly, surgery alone is the gold standard for patients with lo-
calized disease. However, given that this patient presented with a stage
IC1 heterologous Sertoli–Leydig tumor with sarcomatoid features, the
patient's prognosis is poorer than the majority of other patients in her
demographic that have well-differentiated, homologous tumors. In
one clinicopathologic study of 207 patients with Sertoli–Leydig tumors
by Young et al., the prognosis correlated most meaningfully with the
stage and degree of differentiation of the tumor. Also, radiation therapy,
chemotherapy, or a combination of the two, in addition to surgical exci-
sion, was of beneﬁt in the management of the malignant tumors
(Young, 2005). Therefore surgery without adjuvant therapy is ill-
advised in this patient.
The National Comprehensive Cancer Network (NCCN) guidelines
recommend adjuvant chemotherapy with a platinum-based regimen
such as BEP (bleomycin, etoposide, cisplatin), even in an early stage dis-
ease when considering poorly differentiated, high-grade, heterologous
tumors (Homesley et al., 1999). These recommendations are not
based on any large randomized studies in gynecologic malignancy sec-
ondary to the rarity of these tumors, but were borrowed from the land-
mark trials of Einhorn et al. in the treatment of testicular and other germ
cell tumors (Einhorn et al., 1989). One report of 207 patients with ovar-
ian Sertoli–Leydig tumors showed that 18% of patients had tumor that
metastasized or recurred. 59% of patients with high-grade tumors and
19%of thosewith heterologous elements exhibited thesemalignant fea-
tures (Young, 2005). These tumors are exquisitely sensitive to chemo-
therapy, though recurrence rates are high for high-grade histologies.
As this patient has both heterologous morphology with sarcomatoid
features and high-grade histology, she is likely at high risk forrtoli–Leydig tumor. Scatteredmitoses are readily seen in this photomicrograph. Hematox-
les. Hematoxylin and eosin stain. Original magniﬁcation: 100×. 3) Heterologous element
iﬁcation: 200×. 4) Higher power view of Leydig cells and adjacent Sertoli cells. The Leydig
. Original magniﬁcation: 400×.
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gy, heterology, and recurrence rates. According to the EXPeRT trial, spill-
age, stage, and histopathologic differentiation are cornerstones of
outcomeprediction (Young and Scully, 1985). This casewas also unique
in that AFP was signiﬁcantly elevated. Typically, the most common
marker in Sertoli–Leydig tumors is CA-125 (DiSaia and Creasman,
1997). As AFP and CA125 were markers elevated at diagnosis, they are
ideally suited to aid in monitoring of recurrence after treatment. Addi-
tionally, the usual BEP regimen was substituted with intravenous
carboplatin (AUC 6) and paclitaxel (175mg/m2) every threeweeks sec-
ondary to an improved toxicity proﬁle and presumed activity against
higher grade tumors. Due to the presumed higher malignant potential
of the tumor based on having both heterologous elements and
sarcomatoid features, even in the setting of early stage disease, we
will continue to monitor this patient's clinical course closely for
progression-free and overall survival. Ovarian Sertoli–Leydig tumors
are infrequently diagnosed, but this particular neoplasmwas exception-
al in that it displayed heterologous elements and sarcomatoid over-
growth. We will need many more case reports and retrospective
studies such as these, due to the rarity of the tumor, to determine opti-
mal treatment regimens; however we believe carboplatin and taxane-
based therapy for such a unique, high-grade histology may afford the
best outcome for our patient. She is currently without evidence of dis-
ease more than 18 months from her surgery and pregnant with her
third child. Of course we will continue to closely monitor her for recur-
rence with tumor markers and imaging as warranted.Conﬂict of interest
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